BioSpace News Archive

UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration has informed the Company that they were unable to complete review of the Biologics License Application for bimekizumab for the treatment of moderate to severe plaque psoriasis by the Prescription Drug User Fee Action date of October 15, 2021.

Neurocrine Biosciences, Inc. announced that it will present key information from its movement disorder treatments for Parkinson’s disease and tardive dyskinesia at the American Neurological Association 2021 Virtual Annual Meeting being held October 17–19, 2021.

Ocugen, Inc. announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 48,800 shares of its common stock and restricted stock units covering an aggregate of 8,200 shares of common stock to three hired employees.